SEC Filing Summary: ChromaDex Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corp. on March 10, 2014, reporting events occurring on March 6, 2014. The filing discloses the entry into a material definitive employment agreement and the appointment of a new executive officer. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corp.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation:
- Base Salary: $180,000 annually for the new Chief Operating Officer.
- Performance Bonus: Up to 30% of base salary contingent on performance targets.
- Equity Grant: Option to purchase 250,000 shares of common stock.
Material Changes
The primary material change is the appointment of Troy Rhonemus as Chief Operating Officer (COO). Mr. Rhonemus previously served as the Company's Director of New Technology and Supply Chain since January 2013. The filing notes no other transactions exceeding $120,000 involving Mr. Rhonemus since the beginning of the last fiscal year.
Outlook, Risks, and Management Commentary
Management highlights Mr. Rhonemus's over 15 years of experience in operations, supply chain, and business strategy, including significant tenure at Cargill (2006–2012) managing the Truvia enterprise. His role will focus on new technology development to expand the ingredient product portfolio and managing supply chain strategies to meet FDA regulations. The employment agreement is for one year with automatic renewal in successive one-year terms unless terminated. The equity issuance was deemed exempt from registration under Section 4(2) of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the exact terms of the performance targets for the 30% bonus, as they are to be mutually agreed upon by the COO and the Board.
- Confirm the exercise price and vesting schedule for the 250,000 stock options granted, as these details are contained in the attached Exhibit 10.1.
- Review the full Employment Agreement (Exhibit 10.1) for termination clauses and severance provisions not detailed in the summary.
- Clarify the discrepancy between the metadata company name ("Niagen Bioscience, Inc.") and the filing registrant ("ChromaDex Corp.").